Literature DB >> 19473555

Intravenously administered BMSCs reduce neuronal apoptosis and promote neuronal proliferation through the release of VEGF after stroke in rats.

Yu Bin Deng1, Wei Biao Ye, Zhen Zhen Hu, Ying Yan, Ye Wang, Bekomson Francis Takon, Guang-Qian Zhou, Yan Fang Zhou.   

Abstract

BACKGROUND: Transplantation of bone marrow-derived mesenchymal stem cells (BMSCs) could ameliorate neurological deficits after stroke in the rodent.
OBJECTIVE: The purpose of this study was to investigate the potential mechanisms underlying the neuroprotective effects of implanted BMSCs.
METHODS: Ischemic stroke was induced by permanent middle cerebral artery occlusion (MCAo) in Sprague-Dawley rats. BMSCs were intravenously transplanted at 24 hours after MCAo. Neurological function was evaluated using modified neurological severity score and Morris water maze test. Immunohistochemistry and terminal deoxynucleotidyltransferase-mediated dUTP nick-end labeling staining were performed to detect neuronal apoptosis and proliferation. The protein and mRNA levels of vascular endothelial growth factor (VEGF) were determined by ELISA and reverse transcriptase polymerase chain reaction, respectively.
RESULTS: Significant improvement of neurological deficits was found in BMSC-treated rats compared with control animals at 14 and 28 days after MCAo (p<0.05). Histological evaluation showed that BMSCs treatment significantly promoted neuronal survival and proliferation in the ischemic boundary area. The expression of VEGF was predominantly increased in the ischemic hemisphere of BMSC-treated rats compared with the other groups. On the other hand, transduction of VEGF RNAi lentivirus partially attenuated the above described beneficial effects of systemically administered BMSCs.
CONCLUSION: Our data suggest that intravenously administrated BMSCs facilitate neurological function, reduce neuronal apoptosis and promote neuronal proliferation through the release of VEGF.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19473555     DOI: 10.1179/174313209X414434

Source DB:  PubMed          Journal:  Neurol Res        ISSN: 0161-6412            Impact factor:   2.448


  29 in total

Review 1.  Treatment of cerebral ischemia with combination of bone marrow-derived mesenchymal stem cells and Chinese medicine.

Authors:  Ying Guan; Yong-hua Zhao
Journal:  Chin J Integr Med       Date:  2011-09-11       Impact factor: 1.978

2.  VEGF(165) expressing bone marrow mesenchymal stem cells differentiate into hepatocytes under HGF and EGF induction in vitro.

Authors:  Yan Tan; En-Hua Xiao; Li-Zhi Xiao; You-Hong Yuan; Cong Ma; Quan-Liang Shang; Du-Jun Bian; Yan-Hui Li; Zhu Chen; Qian Chang
Journal:  Cytotechnology       Date:  2012-04-04       Impact factor: 2.058

3.  Neuroprotective effect of combined hypoxia-induced VEGF and bone marrow-derived mesenchymal stem cell treatment.

Authors:  Sung Su An; Hong Lian Jin; Keung Nyun Kim; Dong Seok Kim; Joon Cho; Meng-Lu Liu; Jin Soo Oh; Do Heum Yoon; Min Hyung Lee; Yoon Ha
Journal:  Childs Nerv Syst       Date:  2010-03       Impact factor: 1.475

4.  Bone Marrow Stromal Cells Combined With Sodium Ferulate and n-Butylidenephthalide Promote the Effect of Therapeutic Angiogenesis via Advancing Astrocyte-Derived Trophic Factors After Ischemic Stroke.

Authors:  Qian Zhang; Zhen-Wei Chen; Yong-Hua Zhao; Bo-Wen Liu; Nai-Wei Liu; Chien-Chih Ke; Hong-Mei Tan
Journal:  Cell Transplant       Date:  2016-10-21       Impact factor: 4.064

5.  Hypoxia-inducible factor 1-α-AA-modified bone marrow stem cells protect PC12 cells from hypoxia-induced apoptosis, partially through VEGF/PI3K/Akt/FoxO1 pathway.

Authors:  Qian Zhong; Yanfang Zhou; Weibiao Ye; Tuo Cai; Xiuquan Zhang; David Y B Deng
Journal:  Stem Cells Dev       Date:  2012-05-17       Impact factor: 3.272

6.  Interaction between neural stem cells and bone marrow derived-mesenchymal stem cells during differentiation.

Authors:  J U Rong; Zeng Wen; W U Rong; Feng Zhichun
Journal:  Biomed Rep       Date:  2014-12-17

7.  Neuroprotective effects of intravitreal mesenchymal stem cell transplantation in experimental glaucoma.

Authors:  Thomas V Johnson; Natalie D Bull; David P Hunt; Nephtali Marina; Stanislav I Tomarev; Keith R Martin
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-11-20       Impact factor: 4.799

8.  Mesenchymal stem cells protect neurons against hypoxic-ischemic injury via inhibiting parthanatos, necroptosis, and apoptosis, but not autophagy.

Authors:  Deyan Kong; Juehua Zhu; Qian Liu; Yongjun Jiang; Lily Xu; Ning Luo; Zhenqiang Zhao; Qijin Zhai; Hao Zhang; Mingyue Zhu; Xinfeng Liu
Journal:  Cell Mol Neurobiol       Date:  2016-04-04       Impact factor: 5.046

Review 9.  Circulating endothelial progenitor cells: a new approach to anti-aging medicine?

Authors:  Nina A Mikirova; James A Jackson; Ron Hunninghake; Julian Kenyon; Kyle W H Chan; Cathy A Swindlehurst; Boris Minev; Amit N Patel; Michael P Murphy; Leonard Smith; Doru T Alexandrescu; Thomas E Ichim; Neil H Riordan
Journal:  J Transl Med       Date:  2009-12-15       Impact factor: 5.531

10.  Tracking transplanted bone marrow stem cells and their effects in the rat MCAO stroke model.

Authors:  Gregory V Goldmacher; Rena Nasser; Daniel Y Lee; Sargon Yigit; Robert Rosenwasser; Lorraine Iacovitti
Journal:  PLoS One       Date:  2013-03-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.